Loading
A phase 3 trial testing ZL-1310 in non-small-cell lung cancer, now recruiting.
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE) is a phase 3 interventional study registered as NCT07218146, led by Zai Lab (Shanghai) with Zai Lab (US), and recruiting on the registry. Official title: A Randomised, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody-Drug Conjugate (ADC), Compared to Investigator's Choice Therapy in Participants With Relapsed Small Cell Lung Cancer. Planned enrolment is 480 participants (estimated). The study started in 2025-11-30 and primary completion is expected in 2028-06-30. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Extensive-stage small-cell lung cancer, Non-small-cell lung cancer.
Shares Zai Lab, Non-small-cell lung cancer.
Shares Extensive-stage small-cell lung cancer, Non-small-cell lung cancer.
Shares Extensive-stage small-cell lung cancer, Non-small-cell lung cancer.
Shares Extensive-stage small-cell lung cancer, Non-small-cell lung cancer.
Shares Zai Lab, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/